Print overview

September 18, 2014

Bayer Aktiengesellschaft: Bayer plans to focus entirely on Life Science businesses

September 18, 2014

Bayer Aktiengesellschaft: Bayer Board of Management plans to focus entirely on Life Science businesses

September 29, 2011

Bayer Aktiengesellschaft: Phase III Study of Bayer's Rivaroxaban in Patients with Acute Coronary Syndrome Meets Primary Efficacy Endpoint

September 06, 2011

Bayer Aktiengesellschaft: FDA has published documents for discussion at the Advisory Committee on the new drug application for Rivaroxaban

October 31, 2010

Bayer Aktiengesellschaft: Phase III ROCKET AF Study of Rivaroxaban meets its primary efficacy endpoint with Comparable Safety vs. Warfarin